linjc16/ctgov huggingface dataset:
Study of the Evolution Profile of the Renal Doppler in the Perioperative Hepathic Transplantation

Study Overview
=================
Brief Summary
-----------------
Liver transplantation is associated with a modification of the perfusion pressures of the abdominal organs (preoperative portal hypertension in connection with liver pathology, and normalization of the perfusion pressures during surgery). This abrupt change in the infusion regime is probably responsible for an alteration in renal function in some patients, and the identification of renal vascular profiles using Doppler could point to pathological profiles, which should be diagnosed early.

Official Title
-----------------
Study of the Evolution Profile of the Renal Doppler in the Perioperative Hepathic Transplantation - Interest in Predicting the Occurence of Acute Postoperative Renal Faillure

Conditions
-----------------
Acute Renal Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient of full age (≥18 years) Patient operated on at the HUS for a liver transplant, between July 1, 2019 and June 30, 2020. Patients having undergone an evaluation of hepatic and renal vascular profiles perioperatively. Patients hospitalized in the surgical intensive care unit after hepatic transplant surgery. Patient not having expressed, after information, the reuse of his data for the purposes of this research Exclusion Criteria: Patient who expressed his opposition to participating in the study Patient with suspected obstructive acute renal failure Stenosis of renal arteries known at the time End-stage renal disease on dialysis Impossibility of giving the subject informed information (difficulties in understanding the subject, etc.) Subject under safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective analysis of the development profiles of renal dopplers in perioperative liver transplantation |  | Files analysed retrospectily from July 1st, 2019 to June 30, 2020 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Renal Failure, Chronic renal failure, Liver transplant, Renal vascular profiles, Intraoperative hemodynamic instability, Acute tubular necrosis, Renal doppler
Neural Correlates of Intern Speech

Study Overview
=================
Brief Summary
-----------------
The goal is to define what is the nature of intern speech, how it manifests itself, who deal with agency in intern speech and finally what is the role of intern speech in attention tasks.

Detailed Description
-----------------
Intern speech has a main goal in memory, thinking and self-awareness. So this study might bring information in order to better understand any potential adverse effect on depression or anxiety disorders for example.

Official Title
-----------------
Neural Correlates of Intern Speech

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Other: Healthy volunteers
* Device: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 18 and 65 years Right-handed French as mother tongue Visual acuity that allow to read stimulis (contact lens authorized) Healthy subject Exclusion Criteria: Respiratory or cardio-vascular pathology Claustrophobia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Healthy volunteers<br> | Other: Healthy volunteers<br>* Magnetic Resonance Imaging during intern speech, listening, talking, thinking.<br>Device: MRI<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study intern speech | Magnetic Resonance Imaging while talking, thinking, listening | About an hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intern speech, Speech and visual imaging, Mind and oral drift, Cognitive performance, Magnetic Resonance Imaging
A Drug-drug Interaction Study of Oral 1250 mg of Vatalinib Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor in Healthy Sterile or Postmenopausal Female Volunteers

Study Overview
=================
Brief Summary
-----------------
This study will determine the effect of acidic drugs such as proton-pump inhibitors on the pharmacokinetics of Vatalinib under fasting and fed conditions.

Official Title
-----------------
A Phase IB, Open Label, Single Center, Drug-drug Interaction Study of Oral 1250 mg of PTK787/ZK 222584 Administered Under Fasting and Fed Conditions With a Proton-pump Inhibitor (Omeprazole) in Healthy Sterile or Postmenopausal Female Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Vatalinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Healthy female Surgically sterile or post-menopausal At least a weight of 50 kg and have a body mass index (BMI) ≤33.0 Non-smokers or those who smoke 25 cigarettes or less per day Exclusion criteria Use of certain prescription and over the counter drugs Having received an investigational drug within 30 days prior to dosing Donation of plasma or donation or loss of whole blood prior to administration of the study medication Any clinically significant laboratory tests Abnormal cardiac function A positive test for HIV, Hepatitis B or C A positive alcohol test or drug test Known allergy to Vatalinib or Omeprazole Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism and excretion or drugs. Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vatalinib|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the effect of multiple doses of a proton-pump inhibitor on the pharmacokinetics of a single dose of Vatalinib under fasting and fed conditions. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of a single dose of Vatalinib before and after a proton-pump inhibitor under fasting and fed conditions as assessed by adverse events, laboratory values, electrocardiograms, and vital signs. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase inhibitor, Vatalinib, Proton-pump inhibitors, Omeprazole, Healthy Postmenopausal Female Volunteers
Evaluation Of Different Rapid Orthodontic Expansion Devices

Study Overview
=================
Brief Summary
-----------------
Evaluating and comparing the short term effects of different palatal expanders on the amount of palatal expansion and buccal tipping of posterior teeth. Hypothesis: H0: There is no difference in the short term effects between the different palatal expanders. H1: There is a significant difference in the short term effects between the different palatal expanders.

Official Title
-----------------
Comparison of The Short Term Effects of Different Palatal Expanders Using CBCT.

Conditions
-----------------
Cross Bite

Intervention / Treatment
-----------------
* Device: Rapid Expansion of palatal suture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-syndromic adolescent patients. Patients in need for palatal expansion treatment. Average face height. No previous orthodontic treatment. Exclusion Criteria: Syndromic adolescent patients. Patients not in need for palatal expansion treatment. Non-average face height. Previous orthodontic treatment.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Haas group (H)<br>Rapid Expansion of palatal suture device: tooth-tissue supported expander (Haas (H)). | Device: Rapid Expansion of palatal suture<br> <br> |
| Active Comparator: Hyrax (Hx)<br>Rapid Expansion of palatal suture device: tooth anchored expander (Hyrax (Hx)). | Device: Rapid Expansion of palatal suture<br> <br> |
| Active Comparator: Miniscrew-supported (MHx)<br>Rapid Expansion of palatal suture device: bone anchored expander (Temporary anchorage devices(miniscrew)-supported (MHx)) | Device: Rapid Expansion of palatal suture<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amount of skeletal and dental expansion | These are linear measurements which will be measured in millimetres in the first and the second cone beam computed tomography images and the difference will be calculated. | 3 months | 
| Amount of dental inclination | These are angular measurements which will be measured in degrees in the first and the second cone beam computed tomography images and the difference will be calculated. | 3 months |
CUHK Jockey Club HOPE 4 Care Programme - Hand of Hope

Study Overview
=================
Brief Summary
-----------------
The Hong Kong Jockey Club Charities Trust has supported CUHK to launch a three-year project 'CUHK Jockey Club HOPE4Care Programme' to implement four evidence-based advanced rehabilitation technologies in 40 local elderly day care centres and rehabilitation centres, to benefit the community. The interactive intention-driven hand training robotic system is used for neuromuscular rehabilitation of the hand and forearm. This can help stroke survivors to regain their hand functions through motor relearning.

Official Title
-----------------
Jockey Club Tech-based Stroke Rehabilitation Programme - Hand of Hope

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Device: EMG-driven


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: at least six months after the onset of a unilateral ischemic brain injury or intracerebral haemorrhage upper-limb motor impairments due to stroke metacarpophalangeal and proximal interphalangeal joints of fingers can be extended to 180 degree passively spasticity during extension at the finger joints is lower than 3 as measured by the Modified Ashworth Scale detectable voluntary EMG signals from the flexor digitorum and extensor digitorum muscles of the paretic hand have sufficient cognition to follow the experimental instructions Exclusion Criteria: have other neurological, neuromuscular, and orthopedic diseases have shoulder or arm contracture/pain

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EMG-driven<br>The hand training system functions as a biofeedback device which surface electromyography (EMG) sensors are used to capture the user's own muscle signals to activate the system for moving his/her paretic hand. | Device: EMG-driven<br>* The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Action Research Arm Test (ARAT) |  | 3-month follow-up | 
| Fugl-Meyer Assessment Upper Extremity (FMA-UE) |  | 3-month follow-up | 
| Wolf Motor Function Test (WMFT) |  | 3-month follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Ashworth Scale (MAS) |  | 3-month follow-up |
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss

Study Overview
=================
Brief Summary
-----------------
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.

Conditions
-----------------
Cancer Cachexia

Intervention / Treatment
-----------------
* Drug: RC-1291 HCl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Community-dwelling patients ≥ 18 years of age with incurable, histologically diagnosed cancer. Involuntary loss of body weight of ≥ 5 % within the past 6 months Exclusion Criteria: Presently hospitalized or in a nursing care facility. Inability to increase food intake from secondary causes. Liver disease If female-pregnant, breast-feeding or of childbearing potential.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: RC-1291 HCl|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body Weight |  |  | 
| Lean Body Mass |  |  | 
| Functional Performance |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anorexia, Cachexia
FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination

Study Overview
=================
Brief Summary
-----------------
It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.

Official Title
-----------------
Evaluation of Metabolic Changes in FDG PET/CT Imaging After mRNA-based COVID-19 Vaccination

Conditions
-----------------
Vaccine Reaction, Oncology

Intervention / Treatment
-----------------
* Diagnostic Test: F-18 FDG PET/CT imaging
* Biological: Pfizer/biontech mRNA vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients referred for post-vaccination FDG PET/CT imaging Exclusion Criteria: Disseminated metastatic disease, ipsilateral breast cancer or lymphoma that was likely to involve axilla, and patients who had ipsilateral intense axillary uptake or thyroiditis on their prior imaging, were exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: F-18 FDG PET/CT imaging|Oncological imaging|
|Biological: Pfizer/biontech mRNA vaccine|COVID-19 vaccine|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to assess the frequency of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine | Frequency of metabolic changes | 5 month | 
| to assess the FDG intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine | FDG intensity of metabolic changes | 5 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
covid-19, vaccine, pet/ct, FDG, mRNA
TK-based Suicide Gene Therapy for Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether activation of a prodrug after intratumoral gene transfer is safe in humans, and to determine dose levels for further clinical development.

Detailed Description
-----------------
The study is a phase I clinical trial evaluating the intratumoral injection of defective adenovirus containing HSVtk (the thymidine kinase of herpes simplex virus), in patients with advanced hepatocellular carcinoma that were not amenable to curative therapy. The study was conducted in a single center in Spain. Five consecutive cohorts of two patients received increasing doses of the vector by intratumoral injection and equal doses of either intravenous ganciclovir or oral valganciclovir. The dose received by each consecutive cohort of patients was progressively higher according to a prefixed scale.

Official Title
-----------------
Phase I Clinical Trial Of Gene Therapy For Hepatocellular Carcinoma By Intratumoral Injection Of TK99UN (An Adenoviral Vector Containing The Thymidine Kinase Of Herpes Simplex Virus)

Conditions
-----------------
Carcinoma, Hepatocellular

Intervention / Treatment
-----------------
* Genetic: TK99UN


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Unequivocal diagnosis of hepatocellular carcinoma according to histological confirmation or EASL-AASLD criteria Contraindication for surgical treatment of the disease Detectable disease by imaging Ability to give informed consent and to express the willingness to fulfill protocol requirements during the study Exclusion Criteria: Current pregnancy or breast-feeding Acute infection Positive anti-HIV antibodies Hematologic alterations not attributable to hypersplenism, or in any case, intense neutropenia and thrombocytopenia, defined as neutrophil count lower than 0,5/pL or platelet count lower than 20/pL Participation in other clinical trial during the previous month

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events |  | Daily for the first 16 day, monthly thereafter for 6 months, 3-monthly since then | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tumor response by WHO criteria |  | at day 63 and months 4, 6, 9 y 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
primary liver cancer, hepatoma
Mechanisms Behind Antidiabetic Effects by Gastric By-pass

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to develop new strategies in treatment of continuous increasing number of patients with type 2 diabetes by understanding how bariatric surgery cures or improves this condition.

Official Title
-----------------
Mechanisms Behind Antidiabetic Effects by Gastric By-pass

Conditions
-----------------
Diabetes Mellitus Typ 2 and Obesity

Intervention / Treatment
-----------------
* Dietary Supplement: Modifast
* Dietary Supplement: Normal diet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetes typ 2 18-70 years BMI > 35 kg/m2 Treated with oral antidiabetic agents and/or insulin laparoscopic surgery Exclusion Criteria: Pharmacological treatment (other then above) witch could affect glucose metabolism open surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Modifast<br>treated with VLD Modifast 1000 kcal/day in 2 weeks before gastric by-pass, | Dietary Supplement: Modifast<br>* 2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day<br>|
| Placebo Comparator: Normal diet<br>normal diet 2 weeks before gastric by-pass surgery | Dietary Supplement: Normal diet<br>* normal diet 2 weeks before gastric by-pass<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin sensitivity | Insulin sensitivity measured by hyperinsulinemic normoglycemic clamp technique | 12-18 month after gastric bypass | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight reduction |  | 12-18 month after gastric bypass |